我们系统回顾了2019年冠状病毒病(COVID-19)大流行对进展的影响的文献,患病率,和近视的发病率。在PubMed上进行了全面的文献检索,Cochrane中央控制试验登记册,和Scopus数据库。纳入评价的研究评估了近视进展,患病率,和/或发病率作为主要结果。在最初搜索中产生的523篇文章中,23项研究(6项横断面研究和17项队列研究)符合纳入条件。其中有16项在中国进行,各1项在香港进行,土耳其,西班牙,以色列,印度,韩国,和西藏。使用JoannaBriggs研究所关键评估清单进行质量评估。在纳入的研究中,绝大多数人报告说,与COVID-19前相比,COVID-19大流行期间近视改变更大,近视患病率增加.所有三项有关近视发病率的研究均显示,在COVID-19大流行期间,近视发病率增加。COVID-19大流行期间近视进展加速,即使在两项研究中使用低浓度阿托品滴眼液的个体中,但在一项研究中使用角膜塑形术治疗的个体中没有。总的来说,研究发现,COVID-19大流行及其相关的家庭监禁措施通常会增加近视的进展,患病率,和发病率,甚至在使用低浓度阿托品滴眼液的个体中。
We systematically reviewed the literature on the effects of the coronavirus disease 2019 (COVID-19) pandemic on the progression, prevalence, and incidence of myopia. A comprehensive literature search was performed on PubMed, Cochrane Central Register of Controlled Trials, and Scopus databases. Studies included in the
review assessed myopia progression, prevalence, and/or incidence as the primary outcome. Of 523 articles yielded in the initial search, 23 studies (6 cross-sectional and 17 cohort) were eligible for inclusion. Sixteen of these were conducted in China and one each in Hong Kong, Turkey, Spain, Israel, India, Korea, and Tibet. Quality appraisals were conducted with the Joanna Briggs Institute Critical Appraisal Checklists. Of the included studies, a large majority reported a greater myopic shift and increase in myopia prevalence during the COVID-19 pandemic compared to the pre-COVID-19 years. All three studies on myopia incidence showed increased incidence during the COVID-19 pandemic. Myopia progression accelerated during the COVID-19 pandemic, even in individuals using low-concentration atropine eye drops in two studies but not in those using orthokeratology treatment in one study. Overall, the studies found that the COVID-19 pandemic and its associated home confinement measures generally increased myopia progression, prevalence, and incidence, even in individuals using low-concentration atropine eye drops.